Personalized ultrafractionated stereotactic adaptive radiotherapy

RADIATION3 trials

Sponsors

Jonsson Comprehensive Cancer Center, Fujian Cancer Hospital, West China Hospital

Conditions

Colo-rectal CancerColorectal Cancer Liver MetastasisHead and Neck CarcinomaLocalized Head and Neck CarcinomaMetastatic Head and Neck CarcinomaRecurrent Head and Neck Carcinoma

Phase 2

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

RecruitingNCT06788171

Fujian Cancer HospitalColorectal Cancer Liver Metastasis

Start: 2026-05-09End: 2027-09-01Target: 35Updated: 2026-10-01

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer

Not yet recruitingNCT07904130

West China HospitalColo-rectal Cancer

Start: 2026-10-09End: 2029-10-01Target: 32Updated: 2026-10-29

Unknown Phase

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

RecruitingNCT06572423

Jonsson Comprehensive Cancer CenterHead and Neck Carcinoma, Localized Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma +1

Start: 2024-10-25End: 2029-12-16Target: 43Updated: 2026-02-05

Related Papers

A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol.

2024-12-213 citations